China’s public payer, the National Basic Medical Insurance Fund, is putting forward its own definition for innovative drugs, in a bid to raise the bar higher than the current industry standard.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
